誉衡药业(002437.SZ)：普晟普利拟转让誉衡生物20.64%股权 所获价款将用于偿还普晟普利对公司的债务

Core Viewpoint - The company is addressing a debt dispute related to the equity transfer payment of Guangzhou Yuheng Biotechnology Co., Ltd. through an agreement with Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) [1] Group 1: Debt Dispute and Legal Proceedings - The lawsuit regarding the equity transfer payment for Yuheng Biotechnology has entered the execution phase, involving multiple complex steps such as equity assessment, judicial auction, transfer, and payment [1] - The process of selling the equity through conventional judicial procedures and recovering the transfer payment is fraught with significant uncertainty [1] Group 2: Equity Transfer - Pusheng Puli intends to transfer its 20.64% stake in Yuheng Biotechnology to Youpeng Biotechnology (Hainan) Co., Ltd., with the proceeds being used to repay its debt to the company [1]